159 related articles for article (PubMed ID: 29445924)
1. Correction to: The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Kommission Ovar, AGO Study Group, North-Eastern German Society of Gynaecologic Oncology (NOGGO), AGO Austria and AGO Switzerland.
Dueckelmann AM; Fink D; Harter P; Heinzelmann V; Marth C; Mueller M; Reinthaller A; Tamussino K; Wimberger P; Sehouli J
Arch Gynecol Obstet; 2018 Apr; 297(4):847. PubMed ID: 29445924
[TBL] [Abstract][Full Text] [Related]
2. The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the "Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)", the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic Oncology.
Dueckelmann AM; Fink D; Harter P; Heinzelmann V; Marth C; Mueller M; Reinthaller A; Tamussino K; Wimberger P; Sehouli J
Arch Gynecol Obstet; 2018 Apr; 297(4):837-846. PubMed ID: 29356953
[TBL] [Abstract][Full Text] [Related]
3. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer.
Harter P; du Bois A; Mahner S; Pfisterer J; Ortmann O; Marth C; Fink D; Hilpert F; Wagner U; Sehouli J
Geburtshilfe Frauenheilkd; 2016 Feb; 76(2):147-149. PubMed ID: 26941446
[TBL] [Abstract][Full Text] [Related]
4. Ovarian cancer--can intraperitoneal therapy be regarded as new standard in Germany?
du Bois A; Schmalfeldt B; Meier W; Sehouli J; Pfisterer J; ; ;
Int J Gynecol Cancer; 2006; 16(5):1756-60. PubMed ID: 17009967
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancer.
du Bois A; Marth C; Pfisterer J; Harter P; Hilpert F; Zeimet AG; Sehouli J
Int J Gynecol Cancer; 2012 Feb; 22(2):182-5. PubMed ID: 22274314
[TBL] [Abstract][Full Text] [Related]
6. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial.
Harter P; du Bois A; Hahmann M; Hasenburg A; Burges A; Loibl S; Gropp M; Huober J; Fink D; Schröder W; Muenstedt K; Schmalfeldt B; Emons G; Pfisterer J; Wollschlaeger K; Meerpohl HG; Breitbach GP; Tanner B; Sehouli J; ;
Ann Surg Oncol; 2006 Dec; 13(12):1702-10. PubMed ID: 17009163
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).
du Bois A; Pfisterer J; Burchardi N; Loibl S; Huober J; Wimberger P; Burges A; Stähle A; Jackisch C; Kölbl H; ;
Gynecol Oncol; 2007 Dec; 107(3):518-25. PubMed ID: 17910981
[TBL] [Abstract][Full Text] [Related]
8. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).
Wimberger P; Wehling M; Lehmann N; Kimmig R; Schmalfeldt B; Burges A; Harter P; Pfisterer J; du Bois A
Ann Surg Oncol; 2010 Jun; 17(6):1642-8. PubMed ID: 20165986
[TBL] [Abstract][Full Text] [Related]
9. [Diagnosis and treatment of malignant ovarian tumors 2005: recommendations of the Kommission Ovar of the AGO].
Schmalfeldt B; du Bois A; Burges A; Emons G; Fink D; Gropp M; Hasenburg A; Jäger W; Kimmig R; Kiechle M; Kommoss F; Kreienberg R; Kuhn W; Lück HJ; Meier W; Münstedt K; Ortmann O; Pfisterer J; Richter B; Runnebaum I; Schröder W; Sehouli J; Tanner B; Wagner U; Weis J
Zentralbl Gynakol; 2006 Feb; 128(1):11-7. PubMed ID: 16450281
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic effect of different treatment parameters in pressurized intraperitoneal aerosol chemotherapy (PIPAC) on the in vitro proliferation of human colonic cancer cells.
Khosrawipour V; Diaz-Carballo D; Acikelli AH; Khosrawipour T; Falkenstein TA; Wu D; Zieren J; Giger-Pabst U
World J Surg Oncol; 2017 Feb; 15(1):43. PubMed ID: 28183319
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
[TBL] [Abstract][Full Text] [Related]
12. In Vivo Feasibility of Electrostatic Precipitation as an Adjunct to Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC).
Kakchekeeva T; Demtröder C; Herath NI; Griffiths D; Torkington J; Solaß W; Dutreix M; Reymond MA
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):592-598. PubMed ID: 26842487
[TBL] [Abstract][Full Text] [Related]
13. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis.
Demtröder C; Solass W; Zieren J; Strumberg D; Giger-Pabst U; Reymond MA
Colorectal Dis; 2016 Apr; 18(4):364-71. PubMed ID: 26400556
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Wimberger P; Lehmann N; Kimmig R; Burges A; Meier W; Du Bois A;
Gynecol Oncol; 2007 Jul; 106(1):69-74. PubMed ID: 17397910
[TBL] [Abstract][Full Text] [Related]
15. Concentrations of cisplatin and doxorubicin in ascites and peritoneal tumor nodules before and after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal metastasis.
Tempfer CB; Hilal Z; Dogan A; Petersen M; Rezniczek GA
Eur J Surg Oncol; 2018 Jul; 44(7):1112-1117. PubMed ID: 29753612
[TBL] [Abstract][Full Text] [Related]
16. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
Fotopoulou C; duBois A; Karavas AN; Trappe R; Aminossadati B; Schmalfeldt B; Pfisterer J; Sehouli J;
J Clin Oncol; 2008 Jun; 26(16):2683-9. PubMed ID: 18509180
[TBL] [Abstract][Full Text] [Related]
17. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).
du Bois A; Reuss A; Pujade-Lauraine E; Harter P; Ray-Coquard I; Pfisterer J
Cancer; 2009 Mar; 115(6):1234-44. PubMed ID: 19189349
[TBL] [Abstract][Full Text] [Related]
18. Exploring the Spatial Drug Distribution Pattern of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC).
Khosrawipour V; Khosrawipour T; Diaz-Carballo D; Förster E; Zieren J; Giger-Pabst U
Ann Surg Oncol; 2016 Apr; 23(4):1220-4. PubMed ID: 26553440
[TBL] [Abstract][Full Text] [Related]
19. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis.
Robella M; Vaira M; De Simone M
World J Surg Oncol; 2016 Apr; 14():128. PubMed ID: 27125996
[TBL] [Abstract][Full Text] [Related]
20. Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC).
Odendahl K; Solass W; Demtröder C; Giger-Pabst U; Zieren J; Tempfer C; Reymond MA
Eur J Surg Oncol; 2015 Oct; 41(10):1379-85. PubMed ID: 26138283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
